TRANSCATHETER AORTIC VALVE REPLACEMENT

THE EVOLUT™ Hemodynamic ADVANTAGE 

The Evolut TAV's supra-annular, self-expanding valve design delivers exceptional hemodynamics and is the only TAVR device to demonstrate hemodynamic superiority at 1 year in a low risk clinical trial vs. SAVR.1

SEE THE HEMODYNAMIC ADVANTAGE
Animated gif of the Evolut Pro product
pdf Hemodynamic Performance of the EVOLUT™ TAVR Platform  (.pdf)

View comparison data of echocardiographic outcomes following TAVR procedures.

171KB

pdf ACC / AHA Guidelines (.pdf)

Guidelines for the Management of Patients with Valvular Heart Disease.

764KB

pdf Post-TAVR PCI Revival Registry Data (.pdf)

Treating unplanned PCI after TAVR has a high success rate.

261KB

pdf CoreValveTM Notion 8-Year Data (.pdf)

View Hemodynamic Performance rates of the Supra-Annular TAVR Platform.

431KB


SUNDAY, MAY 16, 2021

3:45-4:45 p.m. EST
Virtual Industry Expert Theater session 

A Practical Approach to Shared Decision Making when Treating HVD

Moderated by Dr. Milind Desai

Drs. Purvi Parwani and Howard Herrmann along with Valve Program Coordinator, Kristin Pasquarello, and Patient Advocate, Adam Pick, will share their diverse perspectives on how to embed shared decision-making into daily practice for heart teams. 

Our ACC panel discussion will:

  • Provide clarity on shared decision-making as it relates to heart valve disease treatment
  • Offer actionable insights and resources to reinforce shared decision-making concepts
  • Share examples of how these practices can impact patients

Session Details

Reference

1

Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.

CONTACT

Do you have a question? We’d like to hear from you.

Contact us